Peptide Drug Conjugate Market 2026: Industry Developments, Growth Opportunities & Strategic Insights

Peptide Drug Conjugate market reached an estimated US$ 4.53 billion in 2025 and is expected to reach US$ 25.90 billion by 2035, growing at a CAGR of 19.0% during 2026-2035.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/peptide-drug-conjugate-market?kb

United States: Recent Industry Developments

✅ July 2026: Bicycle Therapeutics reported continued progress in its next-generation Bicycle conjugate pipeline, including radioconjugates, while maintaining a strong cash position to advance oncology programs.

✅ June 2026: Oncopeptides initiated clinical evaluation of its proprietary Peptide Drug Conjugate platform in glioblastoma, marking its expansion beyond multiple myeloma into brain cancer.

✅ March 2026: Avacta Therapeutics opened the Phase 1 FOCUS-01 trial of AVA6103 at U.S. oncology centers in Virginia and Texas, advancing its sustained-release exatecan PDC into clinical testing.

✅ January 2026: Decoy Therapeutics began trading under the DCOY ticker after changing its corporate name from Salarius Pharmaceuticals, reflecting its strategic focus on next-generation peptide-conjugate therapeutics.

Find the right strategic partners to accelerate your business. Get started today:- https://www.datamintelligence.com/partner-identification-enquiry/peptide-drug-conjugate-market?kb

Top Major Key Players 2026:

Novartis, Eli Lilly and Company, Bicycle Therapeutics, Cybrexa Therapeutics, PepGen, PYC Therapeutics, Oncopeptides, Tarveda Therapeutics, Coherent Biopharma, Theratechnologies, Ipsen, RadioMedix, RayzeBio / Bristol Myers Squibb, Fusion Pharmaceuticals / AstraZeneca, PeptiDream, PolyPeptide Group, Bachem, CordenPharma

Key Industry Growth Analysis 2026:

The peptide drug conjugate market is advancing as biopharmaceutical companies develop targeted delivery platforms designed to improve tumor selectivity, therapeutic activity, and the safety profile of oncology treatments.

✅ July 2026: Decoy Therapeutics advanced its peptide conjugate platform using AI and machine learning alongside high-speed synthesis to accelerate the design and development of targeted peptide-conjugate drug candidates.

✅ June 2026: Bicycle Therapeutics presented clinical data supporting its Bicycle Drug Conjugate technology, including zelenectide pevedotin and nuzefatide pevedotin, highlighting the potential of peptide-based targeted delivery in oncology.

✅ May 2026: Avacta Therapeutics reported continued progress with its pre|CISION peptide drug conjugate platform, including development of AVA6103 and advancement of its tumor-activated delivery approach for oncology applications.

✅ April 2026: Bicycle Therapeutics reported AACR 2026 data on nuzefatide pevedotin, an EphA2-targeting Bicycle Drug Conjugate, supporting continued development of peptide-based targeted therapeutics for advanced solid tumors.

✅ March 2026: Avacta Therapeutics dosed the first patient in its FOCUS-01 Phase 1 study of AVA6103, a FAP-targeted peptide drug conjugate carrying exatecan, marking the progression of its next-generation pre|CISION program into clinical testing.

✅ February 2026: Decoy Therapeutics strengthened its focus on next-generation peptide-conjugate therapeutics and advanced its platform for developing candidates targeting oncology and infectious-disease applications.

✅ January 2026: Decoy Therapeutics formally launched under its new corporate identity after Salarius Pharmaceuticals changed its name, emphasizing its strategic focus on AI-enabled peptide-conjugate drug discovery and development.

Regional Market Share:

➠ North America - Largest Share
Strong pharmaceutical R&D infrastructure and high investment in targeted therapies drive peptide drug conjugate adoption. The U.S. leads clinical development, strategic partnerships, and commercialization of precision oncology treatments.

➠ Europe - Significant Growth
Advanced biotechnology capabilities and growing focus on targeted cancer therapies support market expansion. Countries such as Germany, the U.K., France, and Switzerland are strengthening peptide-based drug development and clinical research.

➠ Asia-Pacific - Fastest Growing Region
China, Japan, South Korea, and India are expanding pharmaceutical R&D and biologics manufacturing capabilities. Rising oncology burden, increasing clinical trials, and investments in precision medicine are creating new opportunities for peptide drug conjugates.

Latest M & A 2026:

• July 2026: Samsung Biologics agreed to acquire Switzerland-based PolyPeptide Group for CHF 1.46 billion (approximately US$1.8 billion / KRW 2.7 trillion), securing a global peptide CDMO platform with six facilities across five countries and expanding into peptide-based therapeutics manufacturing.

• July 2026: The Samsung Biologics-PolyPeptide transaction includes the acquisition of 100% of PolyPeptide Group, with Samsung planning to purchase the largest shareholder's 55.65% stake followed by a public tender offer; completion is targeted for December 2026, subject to approvals.

• July 2026: PolyPeptide brought more than 1,000 peptide development and manufacturing programs, approximately 1,500 employees, and production operations in the U.S., Belgium, France, Sweden and India into the proposed Samsung Biologics combination, strengthening peptide manufacturing capabilities relevant to oncology and other peptide-based medicines.

Buy Now & Unlock 360° Complete Market Insights: https://www.datamintelligence.com/buy-now-page?report=peptide-drug-conjugate-market?kb

Japan: Recent Industry Developments

✅ June 2026: PeptiDream and PDRadiopharma completed patient dosing in Japan for the Phase 2 trial of 64Cu-PSMA-I&T, advancing peptide-based targeted radiopharmaceutical development toward potential regulatory submission.

✅ June 2026: PeptiDream announced first-patient dosing of 64Cu-PD-29875, a Claudin18.2-targeting peptide radiopharmaceutical, in a first-in-human Phase 0 imaging study for gastric cancer.

✅ April 2026: PeptiDream announced that collaboration partner Asahi Kasei Therapeutics initiated a Phase 1 trial of AK1940, a macrocyclic peptide discovered using PeptiDream's PDPS platform.

✅ January 2026: PeptiDream continued advancing its PDC strategy across RI-PDC, oligonucleotide-PDC and cytotoxic-PDC programs through its proprietary peptide discovery platform.

Segments Covered in the Peptide Drug Conjugate Market:

By Conjugate Class: Radioligand Peptide Conjugates, Cytotoxic Peptide-Drug Conjugates, Peptide-Oligonucleotide Conjugates, Peptide-Protein and Immune Conjugates, Other Multifunctional Conjugates

By Targeting Peptide: Somatostatin Receptor-Targeting Peptides, PSMA-Targeting Peptides, Integrin-Targeting Peptides, GRPR-Targeting Peptides, Folate and Transporter-Targeting Peptides, Other Receptor-Targeting Peptides

By Payload Type: Radionuclides, Cytotoxic Small Molecules, Oligonucleotides, Immune Modulators and Proteins, Other Payloads

By Linker Technology: Cleavable Linkers, Non-Cleavable Linkers, Enzyme-Responsive Linkers, pH-Responsive and Redox-Responsive Linkers, Self-Immolative and Multifunctional Linkers

By Therapeutic Area: Oncology, Neuromuscular and Genetic Disorders, Ophthalmology, Inflammatory and Autoimmune Diseases, Other Therapeutic Areas

By Route of Administration: Intravenous, Subcutaneous, Intrathecal, Other Routes

By Development Stage: Marketed Products, Phase III and Registration, Phase I/II, Preclinical and Discovery

Regional Analysis for Peptide Drug Conjugate Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/peptide-drug-conjugate-market?kb

Market Growth Drivers:

• Growing demand for targeted drug delivery with improved therapeutic precision

• Increasing R&D activity in peptide-based oncology and targeted therapies

• Expanding use of peptide ligands for selective tumor and cell targeting

• Advancements in peptide synthesis, linker technologies, and drug conjugation

• Growing pharmaceutical investment in next-generation targeted cancer treatments

Unlimited Insights. One Subscription: https://www.datamintelligence.com/reports-subscription?kb

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.